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ABSTRACT 
Characterization of a 30S Ribosomal Subunit Assembly Intermediate Found in 
Escherichia coli Cells Growing with Neomycin or Paromomycin  
by 
Cerrone Renee Foster 
The bacterial ribosome is a target for inhibition by numerous antibiotics.  
Neomycin and paromomycin are aminoglycoside antibiotics that specifically 
stimulate the misreading of mRNA by binding to the decoding site of 16S rRNA in 
the 30S ribosomal subunit.  Recent work has shown that both antibiotics also 
inhibit 30S subunit assembly in Escherichia coli and Staphylococcus aureus 
cells.  This work describes the characteristics of an assembly intermediate 
produced in E.coli cells grown with neomycin or paromomycin. Antibiotic 
treatment stimulated the accumulation of a 30S assembly precursor with a 
sedimentation coefficient of 21S. The particle was able to bind radio labeled 
antibiotics both in vivo and in vitro.  Hybridization experiments showed that the 
21S precursor particle contained 16S and 17S rRNA.  Ten 30S ribosomal 
proteins were found in the precursor after inhibition by each drug in vivo.  In 
addition, cell free reconstitution assays generated a 21S particle during 
incubation with either aminoglycoside. Precursor formation was inhibited with 
increasing drug concentration.  This work examines features of a novel antibiotic 
target for aminoglycoside and will provide information that is needed for the 
design of more effective antimicrobial agents.   
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CHAPTER 1 
INTRODUCTION 
Antimicrobial Resistance 
The increasing emergence of bacterial strains resistant to antimicrobial 
agents has been a persistent medical challenge for decades and is recognized 
as a grave public health problem. For many microorganisms second and third 
generation antibiotics are becoming less effective in treating infection and for 
others a single antibiotic is the only treatment available.  Thus, the discovery of 
novel compounds to counter resistance remains one of the most important goals 
for medical research (Anderson 1999).  
 The design of more effective antimicrobial agents has focused on 
modifying existing drugs that rely on the same molecular targets (Knowles 1997).  
It has been the goal of pharmaceutical companies over the past decades to 
design compounds that combat resistance mechanisms.  Since the discovery of 
penicillin in the 1940s, companies have been continuously improving antibiotic 
effectiveness by manufacturing second, third, and fourth generation 
antimicrobials. This effort to modify existing compounds began 20 years after the 
discovery of penicillin. Yet, by the 1980s almost 80% of Staphylococcus aureus 
isolates had become resistant to penicillin. By 2002, more than 57% of S. aureus 
isolates were resistant to the new classes of antibiotics, leaving the cell wall 
inhibitor vancomycin, as the last drug of choice (Mills 2006). Eventually, 
vancomycin resistant strains emerged and the lipopeptide antibiotic daptomycin 
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was the next compound of choice. Not surprisingly, within a year of FDA approval 
daptomycin resistant strains emerged (Mangili and others 2005). 
A resolution to this problem now focuses on identifying new targets that 
inhibit essential bacterial functions (Chu and others 1996).  However, this has not 
been a straightforward task.  In the past 20 years there has been a decrease in 
the number of FDA approved drugs and of the 10 approved since 1998, only 
daptomycin has a novel drug site. And this was only 43 years following its 
discovery (Spellberg and others 2004; Norrby and others 2005).  
It is very clear that identifying new drug targets should be of foremost 
priority. The targets with the greatest potential have been defined by their 
biological importance. Therefore, examining universal and essential cellular 
functions would be of utmost significance (Lerner and Beutel 2002). Protein 
biosynthesis is a fundamental cellular process and is a well-characterized 
antibacterial target. A number of antibiotic classes function by interacting with the 
fully formed 50S or 30S ribosomal subunits. However, resistance mechanisms 
that modify ribosomal RNA sequences in the fully formed subunits have 
compromised the utility of these compounds (Shaw and others 1998; Beauclerk 
and Cundliffe 1987). On the other hand, little attention has been given to the 
formation of these subunits, which also happens to be an important cellular 
process (Champney 2006). Accurate assembly of ribosomes is undeniably 
essential to the bacterial cell. For this reason, drugs preventing bacterial 
ribosome assembly may be a more fundamental target.   
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30S Subunit Structure and Function 
The bacterial ribosome is a large macromolecular complex whose primary 
task is deciphering the genetic code and stimulating peptide bond formation. This 
is accomplished by both the 30S and 50S subunits. The small subunit sediments 
at 30S and binds mRNA, initiation factors, and the large subunit.  It also 
participates in tRNA selection, thus playing a critical role in translational fidelity.  
The large subunit sediments at 50S and is responsible for peptide bond 
formation and movement of the ribosome along the mRNA sequence (Noller 
1991).   
Resolution of the crystal structure has provided insight into the 30S subunit 
architecture.  About two-thirds of the subunit is RNA and the remaining one-third 
is ribosomal proteins. The secondary structure (Figure 1A) consists of four 
domains that organize into the structural regions shown in Figure 1B denoted as 
the head, body, shoulder, and the platform. The 5' rRNA domain forms the body 
and the central domain establishes the platform.  The 3' minor and major 
domains assemble into the head and shoulder regions respectively (Wimberly 
and others 2000).  Although non-functional, each of the 16S RNA domains can 
assemble separately (Nierhaus 1991; Powers and others 1993; Weitzman and 
others 1993). These four domains are connected by a region known as the neck, 
which is critical for the final 30S conformation and function (Wimberly and others 
2001).   
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A. 
 
B. 
 
Figure 1  Secondary and Three Dimensional Structures of E.Coli 16S rRNA and 
30S Subunit. A.) Secondary structure of 16S rRNA domains.  The central, 3' 
major and minor, and 5' domains are colored; red, blue, purple, and green 
respectively.  The 16S rRNA region enclosed by brackets represents the 
decoding region. B.) 3D structure of the 30S subunit.  The head, platform, 
penultimate stem, and body are formed by the RNA domains shown in A and the 
decoding center is shown by the arrow (adapted from Holmes and Culver 2004). 
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Ribosomal Protein Structure 
While mainly composed of RNA, the significance of ribosomal proteins to 
30S function must not be underestimated.  Both by direct and indirect 
interactions, ribosomal proteins are paramount to the organization of the subunit 
and RNA catalytic activity of the subunit depends on protein association.  For 
example, direct binding of ribosomal proteins assist in domain assembly by 
initiating the tertiary fold between RNA helical junctions (Brodersen and Ditlev 
2005).  In addition, direct contacts with long protein extensions help stabilize the 
final structure.   These extensions are highly basic thereby neutralizing the 
negatively charged RNA backbone.  These narrow extensions are able to make 
direct and specific contacts with the RNA, anchoring the protein deep within the 
RNA folds.  On the other hand, hydrophobic protein-protein interactions stabilize 
the structure indirectly by docking between RNA domains (Brodersen and Ditlev 
2005).  Overall, ribosomal proteins assist in domain organization to create 
functional binding centers. 
The decoding center on the 30S subunit is the binding site for 
aminoglycoside antibiotics.  Located between the head and the body, it is 
primarily composed of RNA.  It is joined by helix 44 in the 3' minor domain with 
loop 530, and projections of 4 ribosomal proteins (Moore and Steitz 2002).  
Some of the current work on 30S structure and function involves characterizing 
the interactions of 16S rRNA with aminoglycoside antibiotics within this site.   
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Structure of Aminoglycosides 
Isolated from Streptomyces fradiae in 1949, neomycin and paromomycin 
are two of several aminoglycosides that bind to the decoding center.  They are 
effective against a number of aerobic and facultative anaerobic microorganisms 
(Kotra and others 2000). This makes them useful in treating abdominal and 
urinary tract infections and preventing endocarditis and bactermia.  In most 
instances, these antibiotics are fast acting bactericidal agents and are 
synergistically effective against nosocomial infections (Jana and Deb 2006).  
The aminoglycosides are four member-ring compounds composed of a 2-
deoxystreptamine linked to several amino sugars.  The positions of the linkages 
distinguish the different aminoglycoside classes.  The 4,5 disubstituted class 
consists of neomycin and paromomycin.  As shown in Figure 2, paromomycin 
and neomycin differ in chemical structure by the functional group attached to the 
C'6 of ring 1.  Paromomycin has a hydroxyl group at this position, while neomycin 
possesses an amino group (Benveniste and Davies 1973, Schroder and Wallis 
2001).  These RNA binding antibiotics have several features that contribute to 
their antimicrobial activity.   Their high positive charge enhances their attraction 
to the negatively charged RNA backbone. In addition, these features also permit 
promiscuous interactions with several other types of RNA motifs (reviewed in Tor 
2006).   
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Figure 2  Structure of Neomycin and Paromomycin. Neomycin has an amino 
group and paromomycin has a hydroxyl group (indicated by the arrow). 
 
Figure 3 shows paromomycin complexed to the ribosomal A site. Rings I 
and II mediate the direct and specific interactions of the antibiotic with the A site.  
The drug binds to the major groove within an RNA pocket created by bases 
A1408, A1492, and A1493.  Ring I forms a pseudo base pair with A1408 and 
stacks above C1409:G1491. The amino groups at positions 1 and 3 shown in 
Figure 3 serve as hydrogen bond donors to U1495 and G1494.  The amino 
groups at positions 1 and 3 of ring II are also essential for binding to the 
decoding site of 16S rRNA. This binding induces a conformational change, that 
facilitates additional binding of the antibiotic to the rRNA (Fourmy and others 
1996,1998; Recht and others 1999).  This same interaction is found with other 
distinct classes of aminoglycosides and explains the general specificity of the 
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neamine core for the A site (Blanchard and others 1998).  Rings III and IV are 
accommodated into the major groove toward the lower stem of the A site.  
Although these rings do not make base specific contacts with the RNA, they 
contribute to the specificity by providing additional positive charges (Schroeder 
and Wallis 2001).  
 
Figure 3  Structure of Paromomycin Complexed to the Ribosomal A Site.  
Paromomycin complexed to the A site is shown in stereo view. Rings I and II of 
paromomycin make base specific contacts with A1408, U1495, G1494, A1493, 
and G1491.  Rings III and IV do not interact within the RNA pocket but contribute 
the antibiotics induced fit.  The blue represents the RNA backbone and tan 
represents paromomycin.  The dashed lines represent possible hydrogen bonds 
(adapted from Schroeder and Wallis 2001).  
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A detailed examination of aminoglycosides and A site interactions 
concluded that the 16S rRNA sequences within the decoding region were 
sufficient to elicit a conformational change in structure (Fourmy and others 1998).  
Footprinting experiments (Recht and others 1999) using an E.coli 16S rRNA 27-
mer oligonucleotide identified the nucleotides that were critical for high affinity 
paromomycin binding.  Subsequently, NMR studies revealed that drug binding to 
these nucleotides produced a change in the conformation of the decoding region 
of the 30S subunit (Lynch and Puglisi 2001) (Figure 4).   
                                                
A B 
Figure 4  Paromomycin Complexed With the A Site Induces a Conformational 
Change.  A.) Nucleotides of the ribosomal A site that are involved in 
paromomycin binding. The triangles represent bases protected from 
dimethylsulfate modification in the presence of antibiotic. B.) Binding of 
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paromomycin results in the “flipping out” of A1492 and A1493 (adapted from 
Pfister and others 2005). 
Inhibition of Translation 
Neomycin and paromomycin are specific for the 30S subunit and induce 
misreading of the genetic code and mistranslation of messenger RNA (Davies 
and others 1965,1968).  In the absence of the antibiotics, translation begins with 
initial selection of an amino acyl-tRNA (cognate) through mRNA base paring. 
Recent structural data has shown that base pairing alone is not sufficient to 
ensure translational fidelity.  Instead, the proofreading capacity depends on a 
highly energetic conformational change that is a prerequisite for cognate tRNA 
binding. Aminoglycosides bypass this discriminatory step facilitating a change in 
structure that allows non-cognate tRNA binding with high affinity (Figure 5). As a 
result, the error frequency is increased (Ogle and others 2001,2002,2003). 
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Aminoglycoside 
Figure 5  Conformational Dynamics of the Decoding Site During tRNA Selection 
and Antibiotic Binding.  A.) A1492 and A1493 are in conformational equilibria 
between the “flipped in” or flipped out states, with the intrahelical states being 
favored in the absence of drug.   In their extrahelical states, A1492 and A1493 
are able to interact with the tRNA anticodon (magenta) and the mRNA codon 
(blue). This interaction being favored in the presence of the cognate tRNA 
anticodon and disfavored in the presence of a non-cognate tRNA anticodon. B.) 
The effects of aminoglycoside binding to the decoding region. The drug (shown 
in brown) binds to the 16S rRNA and shifts the conformational equilibria of A1492 
and A1493 toward their “flipped out” states. As a result, A1492 and A1493 are 
now able to engage in favorable interactions with the codon-anticodon minihelix, 
even when the anticodon is non-cognate (adapted from Pilch and others 2005). 
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Ribosome Assembly 
Rearrangement of the 30S subunit by a molecule less than 1000 times its 
molecular weight has revolutionized current understanding of ribosome structure 
and function.  More than 40 years of investigation on this massive structure have 
revealed details of interactions within the fully formed particle as well as its 
subunits.  In contrast, details of how ribosomal subunits are assembled still 
remain elusive (Culver 2003).   
Several in vitro techniques have been employed to characterize the 
assembly pathway of the 30S subunit (Nomura 1973, Stern and others 1989).  
Ribonuclease cleavage and proteolytic digestion has been used to identify 
elements of 16S rRNA that interact with proteins (Powers and Noller 1995).  
Ribosomal reconstitution and protection experiments have been performed to 
examine protein dependent RNA rearrangements that occur to form the 30S 
subunit (Traub and Nomura 1968; Nashimoto and others 1971; Powers and 
others 1993). Altogether, these data revealed that assembly is a multistep 
cooperative process coupled with RNA transcription in cells. 
The precursor 16S RNA transcript results from cleavage of a larger 
precursor RNA by ribonuclease III. This results in an immature 16S sequence 
with a 115 nt and 33 nt extension at the 5' and 3' ends respectively. While RNA 
maturation is coupled with the addition of ribosomal proteins, the precursor 
sequences may help to promote a conformation required for subunit assembly 
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(Nicholson 1999; Deutscher 2003).  During the initial stage, major RNA 
rearrangements occur forming many of the protein binding sites.  This would 
include sites for primary binding proteins shown in Figure 6A.  As assembly 
proceeds, major changes in protection occur in the 5' domain, then shifting to the 
3' domain.  This is consistent with data revealing a subset of protein dependent 
protections in the 5' and central domains in the 21S intermediate (Figure 6B).  
The addition of tertiary binding proteins results in structural rearrangements with 
protected nucleotides in the 3' minor and major domains, a pattern consistent 
with mature 30S subunits (Holmes and Culver 2004, 2005). 
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A. 
 BODY            PLATFORM           HEAD 
  
                                      
B. 
 Figure 6   5' to 3' Polarity of Ribosomal Protein Binding to 16S RNA. A.) The 
primary binding proteins shown in black bind to the 5' and central domain during 
the early stages of assembly. Proteins shown in green are also primary binding 
proteins but associate midway during assembly. The tertiary domains that are 
formed by each protein is also shown. B.) Secondary proteins that bind to the 5' 
and central domain are shown in pink (adapted from Culver 2003).  
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These data revealed that three major transitions in RNA structure take 
place during subunit formation.  First, initial binding of primary proteins nucleate 
assembly and the subsequent addition of secondary proteins produces a 21S 
intermediate (RI).  Shown in Figure 7 is a possible structural arrangement of this 
particle and its proteins.  In vitro reconstitution assays revealed that the second 
RNA conformational change is solely energy dependent and does not require 
additional protein binding.  This particle sediments at 26S and is critical in 
forming the additional binding sites for the tertiary ribosomal proteins (Mizushima 
and others 1970; Held and others 1973,1974).  Figure 8 is a 30S assembly map 
that shows the interdependencies of protein binding for 30S subunit formation.   
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A
Figure 7  Schematic Representation of the 21S Ribosomal Intermediate.  A 
representation of the structural arrangement of the in vitro 21S ribosomal 
intermediate (RI).  This structure was prepared using the x-ray data of Wimberly 
and others (2000) for the Thermus thermophilus 30S ribosome to 3A resolution 
(PDB Id 1J5E). The neomycin and paromomycin binding site is indicated by A. 
No tertiary proteins are shown in this particle (adapted from Holmes and Culver 
2005) 
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1° 
 
 
 
 
2° 
 
 
 
 
3° 
Figure 8  Representation of 30S Subunit Protein Assembly Map. Primary binding 
proteins are shown in the first row. Secondary and tertiary proteins are shown in 
second and third row respectively. The arrows represent the interdependence of 
each protein. Proteins in red, green, and blue bind to the 5', central, and 3' 
domains respectively (adapted from Culver 2003). 
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Previous Studies 
          Collectively these results suggest that a subset of proteins are critical for 
30S subunit formation and their cooperative role is to facilitate the conformational 
changes in 16S rRNA to form a functional subunit. How this process is impaired 
by aminoglycosides and what 16S rRNA conformational change is needed to 
bind these antibiotics remains unclear (Culver 2003; Champney 2006).  
Recently, the work of Mehta and Champney revealed that 
aminoglycosides have a second inhibitory target on the 30S subunit. These 
results were prompted by the work of previous investigations showing that a 
number of compounds that inhibit translation also prevent ribosome assembly in 
growing cells (Mehta and Champney 2002, 2003).  The macrolides, ketolides, 
lincosamides, and streptogramin B compounds prevent assembly of the 50S 
subunit with little or no effect on the small subunit (Champney 2003).  Inhibition 
by the macrolide antibiotic erythromycin produced an intermediate particle that 
sedimented in the 30S region of a sucrose gradient.  Gel electrophoresis 
revealed that the assembly intermediate was composed of 23S and 5S ribosomal 
RNA from the large subunit, as well as 18 of the 34 ribosomal proteins (Usary 
and Champney 2001).  It has been shown in both E. coli and S.aureus, that 
neomycin and paromomycin inhibit 30S ribosomal subunit assembly in growing 
cells in a similar manner to 50S inhibition, producing a 21S assembly 
intermediate.  It was shown that these antibiotics are specific for 30S assembly, 
with little or no effect on 50S assembly (Mehta and Champney 2002, 2003).  This 
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work was the first identification that aminoglycosides inhibit 30S subunit 
assembly in vivo.  Unlike the 50S assembly intermediate, the 21S precursor 
(p30S) remains uncharacterized.  
The model for assembly inhibition in Figure 9 proposes that in the 
absence of antibiotic, assembly proceeds normally forming a functional subunit 
with a binding site (A). In the presence of neomycin or paromomycin at the IC50, 
half of the cells go on to form functional subunits that can be inhibited in 
translation (Figure 9B) and the other half are inhibited during assembly. It 
remains unclear whether these pathways are identical.  Last, the intermediate 
would be degraded by cellular ribonucleases in a similar manner as the large 
subunit (Silvers and Champney, 2005).   
This work is intended to explore the observation that many antibiotics that 
inhibit the translational functions of the bacterial ribosome also prevent its 
assembly in microbial cells.  30S assembly inhibition by neomycin and 
paromomycin has been examined in vivo by characterizing the rRNA and protein 
composition of the precursor particle. 
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Figure 9  Model of 30S Subunit Assembly in E.coli Cells. A.) The pathway of 
normal 30S assembly. B.) In the presence of the aminoglycoside, subunit 
assembly stalls and an assembly intermediate accumulates with the drug bound 
in a site (I) similar to the site found on the mature 30S subunit (A).  Cellular 
ribonucleases degrade the intermediate into rRNA oligonucleotides and free 
ribosomal proteins (adapted from Usary and Champney 2001).   
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CHAPTER 2 
 
MATERIALS AND METHODS 
 
 
Media 
 
Tryptic Soy Broth:  30 g tryptic soy broth in 1 L dH2O. 
Minimal Media: 100 ml 1X A-salts, 1 ml 20% glucose, 0.1 ml 20% MgSO4, and 
0.05 ml thiamin [1mg/ml]. 
5X A-salts: 52.5 g K2HPO4, 22.5 g KH2PO4, 5 g (NH4) 2SO4, and 2.5 g Na 
citrate×(2H2O) to 1 L with dH2O.  
 
Buffers 
S-Buffer:  10 mM Tris-HCl (pH 8.0), 50 mM NH4Cl and 0.5 mM Mg Acetate.   
R-Buffer:  10 mM Tris-HCl (pH 8.0), 50 mM NH4Cl, 10 mM Mg Acetate, and 0.2 
mM β-mercaptoethanol. 
Ribosome Wash:  10% sucrose, 2M NH4Cl, 10 mM MgCl2, 10 mM Tris-HCl  
(pH 8.0) 
Binding Buffer: 50 mM Tris-HCl (pH 7.8), 80 mM KCl, 16 mM Mg Acetate 
Wash Buffer: 25 mM Tris-HCl (pH 7.8), 60 mM KCl, 20 mM Mg Acetate 
10X MOPS Buffer:  0.2 M MOPS (pH 7.0), 20 mM sodium acetate, 10 mM EDTA 
(pH 8.0). 
RNA Resuspension Buffer: 150 µl formamide, 36 µl formaldehyde, 30 µl 10X 
MOPS buffer.  
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 RNA Running Buffer:  900 ml sterile dH2O, 100 ml 10X MOPS buffer.   
Alkaline Transfer Buffer:  3 M NaCl, 8 mM NaOH, and 2 mM Sarkosyl.  
5X Neutralizing Buffer:  0.5M Na2HPO4, 0.5M NaH2PO4 in 1 L dH2O 
Formamide Hybridization Buffer:  50% formamide, 5X SSC, 0.1 % sarkosyl, 
0.02% SDS, 200 µg/ml BSA, with 1X background quencher.  
TE buffer: 10 mM Tris-HCl (pH 8.0), 1 mM EDTA.  
20X SSC: 3.0 M NaCl, 0.3 M Na citrate and HCl to adjust pH to 7.0. 
 
Protein Electrophoresis Buffers 
1st dimension sample buffer: 0.01 M Bis-Tris (pH 4.2), 7.6 M urea, 6mM acetic 
acid, 0.14 M β-mercaptoethanol in 10 ml dH2O. 
1st dimension upper tank buffer: 0.01M Bis-Tris (pH 3.8) and 3.6 mM acetic acid 
in 1 L dH2O. 
1st dimension lower tank buffer: 0.01 M Bis-Tris (pH 6.0) and 0.4 mM acetic acid 
in 1 L dH2O. 
1st dimension separating gel solution: 0.4 M Bis-Tris (pH 5.5), 0.45 mM acetic 
acid, 4% acrylamide, 0.66% bis-acrylamide and 8M urea. 
2nd dimension separating gel solution: 0.44M glacial acetic acid (pH 4.5), 0.44M 
KOH, 18% acrylamide, 0.5% bis-acrylamide and 6M urea. 
2nd dimension running buffer: 0.93M glacial acetic acid (pH 4.0) and 0.93M 
glycine. 
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Reconstitution Buffers 
Buffer #4: 20 mM Tris-HCl (pH 6.0), 4 mM Mg acetate, 400 mM NH4Cl, 0.2 mM 
EDTA and 5 mM β-mercaptoethanol. 
Buffer #5: 20 mM Tris-HCl (pH 6.0), 4 mM Mg acetate, 400 mM NH4Cl, 0.2 mM 
EDTA, 5 mM β-mercaptoethanol, and 6M urea 
Buffer #7: 10 mM Tris-HCl (pH 7.6) and 4 mM Mg acetate. 
Buffer # 9: 110 mM Tris-HCl (pH 8.0), 4 mM Mg acetate, 4 M NH4Cl, 0.2 mM 
EDTA and 20 mM β-mercaptoethanol. 
Bacterial Cell Growth 
Escherichia coli ribonuclease deficient strain D10-1, an RNase I mutant 
(Gesteland 1966), and SK901 (Mehta and Champney 2002) were used in this 
study.  Cells were grown in either tryptic soy broth or minimal media (A salts and 
0.2% glucose) (Miller 1972).  Fresh media was inoculated with an overnight 
bacterial culture.  The growth rate was measured by following the increase in cell 
density in a Klett Summerson calorimeter at 27°C. Neomycin, paromomycin, and 
streptomycin were added at a cell density of 15 Klett units. The cells were 
harvested after two cell doublings (60 Klett units). 
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Analysis of Ribosomal RNA 
Primer Design  
A 101 nt 16S DNA probe was generated by amplifying a region of 16S 
DNA from plasmid pKK3535 using the polymerase chain reaction. PCR reaction 
mixtures contained 45μl of PCR Supermix High Fidelity reagent (Gibco BRL), 1μl 
of plasmid DNA (6.5ng), 1μl (10 pmol) of 16S forward and reverse primers, and 
2μl of sterile water.  The forward primer was: GGAGGAAGGTGGGGATGACG 
and the reverse primer was ATGGTGACGGGCGGTGTG (nt. no. 1173-1414) 
from Life Technologies.  Samples were amplified for 35 cycles under the 
following conditions: denaturation at 94°C for 30 sec, annealing at 57°C for 30 
sec, and extension at 72°C for 30 sec.  The PCR product was purified by 
extraction with an equal volume of phenol and chloroform and precipitated with 2 
volumes of ethanol.  Single stranded DNA probes for 16S rRNA precursor 
sequences were purchased from One Trick Pony Corporation.  The sequence for 
the 5' precursor is: 5'-CGC TCA AAG AAT TAA ACT TCG-3' and the 3' precursor 
is: 5'- ACG CTT CTT TAA GGT AAG G-3' (Figure 10).  The PCR product and 
precursor probes were resuspended in sterile water and labeled with biotin using 
the Label-IT biotin labeling kit (Mirus).  
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5'UGUGUGGGCACTCGAAGAUACGGAUUCUUAACGUCGCAAGACGAAAAAUGAAUACCGAAGUCUCAAG
AGUGAACACGUAAUUCAUUACGAAGUUUAAUUCUUUGAGCGUCAAACUUUUAAAUUGAAGAGUUUGA
UCAUGGCUCAGAUUGAACGCUGGCGGCAGGCCUAACACAUGCAAGUCGAACGGUAACAGGAAGAAGC 
 
 
                                                               16S MATURE SEQUENCE 
  
 
CUGGGGUGAAGUCGUAACAAGGUAACCGUAGGGGAACCUGCGGUUGGAUCACCUCCUUACCUUAAAGA
AGCGUACUUUGUAGUGCUCACACAGAUUGUCU 3' 
 
Figure 10  Upstream and Downstream Regions of 16S RNA Sequence.  
Nucleotides in red represent the probes for the precursor region.  The 5' probe 
begins +10 nt upstream of the mature sequence.  The 3' probe overlaps with the 
last four nucleotides of the mature sequence.  
Slot Blot Hybridization 
E. coli cells were harvested after two cell doublings by centrifugation in a 
Beckman centrifuge (J2-21) at 6,000 rpm for 12 minutes in a JA21 rotor.  Cell 
pellets were washed with sterile S-buffer. Washed pellets were centrifuged again 
at 6,000 rpm for 12 minutes.   The cell pellets were stored at -70°C before cell 
lysis.   
Cells were lysed with lysozyme by the freeze thaw method.  Washed cell 
pellets were thawed at room temperature and resuspended in 200 µl of S- buffer 
and 15 µl of a 5 mg/ml solution of lysozyme was added.  Cells were allowed to 
incubate at room temperature for 15 to 20 minutes and were then subject to a 
freeze-thaw process. Cells were frozen for 5 minutes at -70°C and then thawed 
at room temperature.  This procedure was repeated twice. DNA was digested in 
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cell lysates by adding 2 units of DNAase I to each sample.  The samples were 
centrifuged at 6,000 rpm for 12 minutes.  
Cells lysates were added to 5-20% sucrose gradients and spun at 39,000K 
for 5.5 hrs in a SW40 rotor.  RNA for slot blot hybridization was prepared from 
sucrose gradient fractions. Any DNA that would present contamination for the 
slot blot analysis would have been separated on the gradient and not present in 
30S and 50S subunit fractions. Each fraction from the sucrose gradient was 
digested with 10 μg of proteinase K (Fluka) in 0.1 % SDS for 2 hours at 44°C 
followed by ethanol precipitation (2 volumes) and resuspended in 0.2 mL of 
dH2O.  RNA from each fraction was applied to a nylon membrane (Nytran) using 
a slot blot apparatus. The membranes were washed with 0.5 mL of TE buffer and 
RNA was cross linked using a UV oven. The membranes were placed in 50 ml 
plastic corex tubes with 15 ml of 1X pre-hybridization solution (MRC, Inc.) and 
allowed to incubate at 42°C for 30 minutes in a hybridization incubator (Fisher-
Biotech).  The pre-hybridization buffer was discarded and the membranes were 
hybridized with the biotinylated 16S DNA probe overnight at 42°C with 4 pmol of 
denatured 16S probe in 7 ml of hybridization buffer and 1X background quencher 
(MRC Inc.). The probe was denatured by mixing with 0.1 volume of Mirus 
Denaturation Buffer D1 and incubating at room temperature for 5 minutes.  The 
solution was chilled on ice and mixed with 0.1 volume of Mirus Neutralization 
Buffer N1 and incubated at room temperature for 5 minutes. 
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The probe was detected using the North to South Chemiluminescent 
Detection Kit (Pierce) using a horseradish peroxidase strepavidin conjugate for 
biotin detection. The membrane was covered with plastic wrap on a glass plate 
and exposed to Fuji Medical X-ray film. X-ray film was developed by soaking the 
film in Kodak GBX developer for 1-5 minutes, rinsing in H2O, soaking in fixer and 
replenisher for 1-5 minutes, followed with a final rinsing in H2O.  The average 
spot intensity for each fraction was quantified by scanning the film using an Alpha 
Innotech image analysis system. 
Northern Blot Analysis 
Total RNA was isolated from E. coli cells using the Aqua Pure (Bio-Rad) 
RNA isolation kit.  Total RNA (5 μg) from cells treated with or without antibiotic 
was denatured by heating at 55°C for 15 min and electrophoresed on a 1.8% 
agarose gel for 2.5 hours (Farrell 1993).  RNA was detected by Northern blot 
analysis. The RNA was blotted onto nylon membranes using a Turboblot 
apparatus.  RNA transfer was performed using an alkaline transfer buffer for 2 
hours.  After the transfer, gels were checked for RNA by ethidium bromide 
staining. The membrane was neutralized in 1X neutralizing buffer and the RNA 
was cross-linked to the membranes using a UV oven (Fisher-Biotech).   
Hybridization was performed as described for the slot blot experiment except the 
membranes were hybridized separately for 20 hrs with the 5', 3', and 16S probes 
at 32°C with hybridization buffer.  The membranes were then washed in 6X SSC 
for 15 min. The second stringency wash contained 0.1X SSC and 0.5% SDS for 
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15 min at 50°C. Hybridization and stringency wash temperatures were performed 
at 42°C for the 16S probe.  The North to South Chemiluminesent Kit was used 
for probe detection as previously described. 
Two-Dimensional Polyacrylamide Gel Electrophoresis 
Cells were grown in A salts minimal media (100 ml) with 35S-methionine 
(5µCi/ml) and supplemented with 0.4 μg/ml of 19 amino acids excluding 
methionine.  Radio labeled cell lysates were spun through 5-20% R buffer 
sucrose gradients as previously described for RNA analysis. Fractions containing 
the precursor region and 30S subunits were collected and pooled. To detect any 
contamination, the pooled region was respun on a sucrose gradient and the 
precursor region was collected.   Non-radio labeled 30S subunits (100μg) were 
added to the pooled fractions as a carrier.  Total ribosomal proteins were isolated 
by treating subunits with 0.1 volume of 1M Mg Acetate and 2.2 volumes of glacial 
acetic acid for 45 min at -20°C to extract the RNA. Next samples were spun at 
10,000 rpm for 30 min. The RNA pellet was discarded and the ribosomal proteins 
were precipitated from the supernatant with 5 volumes of acetone for 3 hrs at 
4°C.   Following centrifugation at 10,000 rpm for 30 min, the pellet was dried and 
resuspended in sample buffer. The labeled proteins separated by two-
dimensional gel electrophoresis as previously described (Geyl and others 1981; 
Usary and Champney 2001) the proteins were detected by Comassie Blue 
staining. The protein spots were excised from the gel, digested with 0.5 ml 30% 
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hydrogen peroxide at 85°C for 3 hrs and the amount of radioactivity was 
determined by liquid scintillation counting.  Data were normalized by dividing by 
the number of methionine residues for each protein (Giri and others 1984).   
Aminoglycoside Radio Labeling 
Neomycin and paromomycin were radio labeled by reductive methylation 
with 3H-formalydehyde as previously described (Champney 1989). During the 
reductive methylation process protons on the amino groups of the 
aminoglycoside were replaced with tritiated methyl groups from the 3HCOH.  
Antibiotics were incubated at 37°C for 30 minutes under the following conditions: 
neomycin and paromomycin (100μg), 3H formaldehyde (20nmol), NaCNBH3 
(20µg), and 10mM NaPO4 buffer pH 6.6.  The labeled antibiotic was separated 
from free formaldehyde by chromatography on a Bio-Gel P2 column in 0.1M NH4 
acetate buffer. Fractions containing the labeled drug were pooled, lyophilized and 
resuspended in 200 μl of water.  The specific activity for 3H-neomycin and 3H-
paromomycin was 3.3mCi/mol, which was determined by measuring 2μl of the 
sample by liquid scintillation counting.  
 Thin layer chromatography was performed to determine the number of 
methylated amino groups (Roets and others 1995). Paromomycin and neomycin 
(labeled and unlabeled) were dissolved in water at a concentration of 4.0 mg/ml 
and 1.0 µl of each sample was applied to a cellulose TLC plate. The mobile 
phase solution consisted of methanol-20% sodium chloride (vol/volume) (15:85).  
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The mobile phase solution was equilibrated for at least 1 hour before use and the 
mobile phase ascended over 12 cm in 2 hours. The plate was dried and 
fluorography was performed by adding scintillator solution consisting of 7% 
(weight/volume) solution of 2,5-diphenyloxalazole (scintillation grade) in ethanol 
that was poured over the chromatograph as described (Toutchstone and Dobbins 
1983).  The chromatograph was used to expose x-ray film at -70°C for 2 days.  
Figure 11 shows the autoradiograph of the labeled neomycin and paromomycin. 
In addition to radio labeling, 3H-paromomycin was also purchased from Moravek 
Biochemicals (0.6 Ci/mmol) 
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Figure 11  Identification of Radiolabeled NH3 Groups of 3H-Paromomycin and 3H-
Neomycin.  A.) Radioactive profile of fractions collected from a Bio Gel P2 
column containing 3H-paromomycin.  The smaller peak represents radio labeled 
  P       N 
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antibiotic and the larger free 3H-formaldehyde. B.) Thin layer chromatography of 
aminoglycosides prepared by reductive methylation.  P represents 3H-
paromomycin and N, 3H-neomycin. 
In Vivo Binding Assay 
E.coli cells were grown in minimal media in the presence of 3H-neomycin 
or 3H-paromomycin (0.5μCi/ml) 6µg/ml, and streptomycin at 2µg/ml.  The 
antibiotics were added to cells at a Klett of 20, corresponding to 1.6 x 108 
cells/ml. The cells were grown for two cell doublings and immediately harvested 
and lysed by the freeze thaw method as described above. Cell lysates were spun 
through 5-20% S buffer sucrose gradients for 5.5 hrs at 39,000 rpm in a SW40 
rotor. Fractions were collected using an ISCO UV absorbance monitor and the 
amount of 3H-antibiotic binding was measured by liquid scintillation counting.   
In Vitro Binding Assay 
30S, 50S, and p30S particles were isolated from sucrose gradients of cell 
lysates as described for protein analysis. Subunits and precursors were pelleted 
in a Ti50 rotor at 45,000 rpm for 16 hrs.  The 21S precursor particle was dialyzed 
against 100 ml of R buffer to remove bound antibiotic.  Increasing amounts of 3H-
paromomycin (Moravek Biochemicals) were incubated with 5 pmoles of p30S, 
30S, or 50S in binding buffer at 37°C for 15 minutes.  Particles with bound 
antibiotic were captured on a 0.45 μm Millipore filter and washed with 10mL of 
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wash buffer.  Bound 3H-paromomycin was detected by liquid scintillation 
counting. 
Ribosomal Subunit Reconstitution 
Isolation of RNA and Proteins 
Ribosomal RNA was isolated from 30S subunits.  These subunits were 
from sucrose gradient lysates that were pelleted at 45,000 rpm for 18 hrs in a 
Ti50 rotor.  The pellets were resuspended in 1 ml of R buffer. The RNA was 
extracted using 0.1 volumes of 10% SDS and 1.2 volumes of phenol.  The 
mixture was vortexed for 8 min and spun at 10,000 rpm for 10 min.  Two volumes 
of ethanol was added to the aqueous phase to precipitate RNA. After 2 hrs at  
- 20°C the RNA was pelleted by centrifugation at 9,000 RPM for 45 min and 
resuspended in buffer #7. 
Total ribosomal proteins were isolated from 30S subunits by adding 0.1 
volume of 1M Mg Acetate and 2.2 volumes of glacial acetic acid for 45 min at  -
20 ° C, followed by centrifugation at 10,000 rpm for 30 min. The RNA pellet was 
discarded and the ribosomal proteins were precipitated from the supernatant by 
adding 5 volumes of acetone for 3 hrs at 4°C.   Following centrifugation at 10,000 
rpm for 30 min, the pellet was dried and resuspended in 1 ml of buffer #5.  The 
proteins were dialyzed for 2 hrs against 100 ml of buffer #4.   
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30S Subunit Reconstitution 
Reconstitution was performed as previously described (Spedding 1990). 
3H-16S rRNA was isolated from cells grown with 1μg/ml 3H-uridine.  In order to 
halt further isotope incorporation after two cell doublings, uridine (50 µg/ml) was 
added in excess to each culture.  After a 15 min chase period, 3H-30S subunits 
were isolated from sucrose gradients and the 3H-16S rRNA was extracted as 
described above. Then 22 μg of 3H-16S rRNA and 200μg of total 30S ribosomal 
proteins were incubated at 40°C in buffer # 9 for 20 min and immediately added 
to ice.  To examine assembly inhibition in vitro, neomycin and paromomycin were 
added to the reconstitution mixture at  final concentrations of 0.04, 0.2, and 
0.4µM. Mixtures were then layered on 5 to 20% reconstitution buffer sucrose 
gradients and centrifuged at 39,000 rpm for 5.5 hr in a SW40 rotor. Gradient 
fractions were collected and counted by liquid scintillation. 
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CHAPTER 3 
 
RESULTS 
 
 
Inhibition of Bacterial Cell Growth 
 
E.coli cells were grown at 10μg/ml of neomycin or paromomycin, which 
was determined in previous studies (Mehta and Champney 2002), for 
experiments examining the assembly inhibition.  In the absence of the antibiotics 
cell growth continued exponentially (Fig 12A). Cell growth with 10μg/ml of 
neomycin or paromomycin decreased the growth rate by more than 50%, with 
neomycin having a greater inhibitory effect. In certain experiments, streptomycin 
was used to enhance the binding of neomycin and paromomycin to ribosomal 
subunits (Lando and others 1978). Streptomycin is an inhibitor of protein 
synthesis, so at 2 μg/ml there was a small lag in cell growth compared to cells 
grown without antibiotic (Figure 12B). Cells grown with streptomycin in 
combination with neomycin or paromomycin, were still inhibited by 50%.   
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Figure 12  Cell Growth of E.coli SK901 Growing in the Absence and Presence of 
Neomycin, Paromomycin, and Streptomycin.  A.) Cells were grown in the 
absence of the antibiotic (□), or with neomycin (10µg/ml) (∆), or paromomycin 
(10µg/ml) (○). B.) Cells grown with streptomycin alone at 2μg/ml (◊), or with 
streptomycin and neomycin (▲), or with streptomycin and paromomycin (●), or 
no antibiotics (□). 
 
Identification of the 30S Ribosomal Assembly Intermediate 
 Mehta and Champney showed cells treated with neomycin and 
paromomycin produced a precursor particle with a sedimentation coefficient of 
21S (2002).  The intent of this experiment was to determine if this precursor 
particle could be successfully isolated from cells for further analysis.  Sucrose 
gradient profiles show 30S assembly inhibition (Figure 13) and the accumulation 
of a p30S particle in cells grown with paromomycin or neomycin.  Cells were 
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lysed and separated under high magnesium conditions (10mM) to ensure 
complete separation of the precursor from mature subunits.  In the presence of 
the antibiotics, immature ribosomes are unable to associate with 50S particles 
and prevent 70S particle formation.  When treated with antibiotics there was a 
greater accumulation of RNA in the precursor region of the gradient.  The 
gradient profile in Figure 13B represents pooled fractions from sucrose gradient 
lysates from neomycin treated cells shown in Figure 13A.  Mehta and Champney 
have already shown that the 30S assembly intermediate sediments in this region 
of the gradient (2002,2003) and Figure 13B confirms that in the presence of 
neomycin a  21S precursor particle does accumulate in this region and can be 
successfully isolated.  Similar results were obtained using paromomycin (data not 
shown). 
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Figure 13  Sucrose Gradient Profiles of E.coli SK901 Treated With Neomycin or 
Paromomycin. A.) Sucrose gradient profiles of cell lysates. Cells were grown in 
the absence of the antibiotic (■), or with neomycin (10μg/ml) (∆), or paromomycin 
(10μg/ml) (○).The cells were lysed and layered on R buffer sucrose gradients 
and 3H-uridine incorporation determined by liquid scintillation. B.) The p30Sneo 
assembly intermediate (∆) collected from fractions 9-15 of the gradient from 
neomycin treated cells (Figure 13A). The same fractions were collected for the 
p30S particle from untreated cells (■). 
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Identification of 16S RNA in the 21S Intermediate 
 
To substantiate that the p30S assembly intermediate was indeed a 
precursor to the 30S subunit, the rRNA content was examined in cells grown with 
neomycin and paromomycin.  RNA isolated from sucrose gradient fractions of 
cell lysates treated with or without antibiotic was hybridized with a 16S DNA 
probe, and the signal was negative in the precursor region for control cells and 
cells treated with streptomycin (2μg/ml).  While streptomycin is an inhibitor of 
protein synthesis, it has no effect on assembly inhibition (Figure 14A).  Relative 
spot intensities of 16S rRNA hybridization of fractions from cells treated with 
neomycin (Figure 14B) shows the presence 16S rRNA in the p30S and 30S 
subunit regions of the gradient. Similar results were also found in cells treated 
with paromomycin, but with lesser amounts of 16S hybridization to smaller RNA 
fragments that sediment in fractions 1-5 of the gradient (Figure 14C).            
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Figure 14  Hybridization Analysis of Sucrose Gradient Fractions From Antibiotic 
Treated and Control Cells. Slot blots of 16S rRNA hybridization of RNA isolated 
from sucrose gradient fractions of cells grown with or without antibiotic. A.) Cells 
grown without antibiotic (■) or with streptomycin (2μg/ml) (◊). B.) Cells grown with 
neomycin alone (10μg/ml) (▲), or with neomycin and streptomycin (2μg/ml) (◊). 
C) Cells grown with paromomycin alone (10μg/ml) (●), or with paromomycin and 
streptomycin (2μg/ml) (◊).  
 
Northern Hybridization Analysis of 16S and Precursor RNA 
 
Maturation of 16S rRNA is coupled with 30S subunit assembly and 
unprocessed RNA are not present in a mature functional 30S subunit.  However, 
an accumulation of precursor rRNA occurs in cells defective in 30S or 50S 
subunit assembly (Himeno and others 2004; Kaczanowska and Aulin 2005). 
Therefore, gel electrophoresis was employed to examine the type of rRNA 
species in the p30S intermediates isolated from drug treated cells. Total RNA 
from drug treated cells was analyzed on a 1.8% agarose gel (Figure 15A). Lane 
1 contains mature 16S RNA isolated from 30S subunits.  Precursor RNA as well 
as mature 16S RNA was identified in control cells (Lane 2). The cells were grown 
at a lower than normal temperature (27°C) and because 16S maturation is 
coupled with assembly, small amounts of natural precursor (p30S) are available.  
A band slightly larger than 16S was identified in cells treated with neomycin and 
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paromomycin (Lanes 3 and 4) corresponding to the position of 17S RNA. The 
amount of 16S remained the same and treatment of cells with either antibiotic 
had no effect on 23S rRNA (Lanes 2-4). 
Northern hybridization was performed using probes specific for the 3' and 5' 
precursor sequences of 17S rRNA to determine the effects on RNA processing. 
Hybridization with the 5' probe to RNA from the gel shown in Figure 15A identified 
immature RNA in both antibiotic treated and untreated cells (Figure 15B). 
However, greater amounts of 17S rRNA were observed with neomycin and 
paromomycin (lane 3 and 4) using the 5' probe.  In contrast, 17S RNA detected 
using the 3' probe was seen only in antibiotic treated cells with increased levels in 
the presence of paromomycin (lane 4).  The reduced amount of 16S RNA in drug 
treated samples was probably a result of RNA degradation. 
Densitometry measurements of the relative amounts of RNA from Northern 
blots hybridized with mature and precursor 16S probes are shown in Figure 16. 
The amount of 16S RNA remained the same in absence and presence of 
antibiotic.  In the absence of antibiotic, there was a greater amount of 5' precursor 
compared to 16S RNA and 3' immature RNA in drug treated cells.  However 
compared to non-treated cells, treatment with neomycin caused a 2.5 fold increase 
in 3' precursor and a 1.5-fold increase in 5' RNA.  In the presence of paromomycin, 
there was a 4.5 and 1.7 fold increase in 3' and 5' precursor RNA respectively.  
53 
 
                            
A. B. 
           1        2         3        4 
 
  23S 
 
 
  16S 
 
Figure 15  Identification of immature 17S rRNA of the 21S ribosomal assembly 
intermediate. A.) Agarose gel of rRNA from antibiotic treated cells showing the 
size of rRNA present in cells treated with or without antibiotic.  Total RNA (5μg) 
was electrophoresed on a 1.8% MOPS-formaldehyde agarose gel for 2.5 hrs at 
50 volts.  16S rRNA was identified in untreated and drug treated cells (lanes 2-4) 
as compared to mature 16S RNA isolated from 30S subunits (lane 1).  The band 
above the 16S RNA represents the position of 17S RNA (lane 3 and 4). B.) A 
Northern blot of RNA from the agarose gel in 15A after hybridization with 5' and 
3' probes specific for 17S RNA and an internal 16S probe. 
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Figure 16  Relative Amounts of 17S rRNA from Cells Treated With Neomycin and 
Paromomycin.  The relative intensity from integration of Northern blots hybridized 
with mature and precursor 16S probes are shown as a fold increase.  The 
amount of 16S rRNA was set as one.  A.) 16S probe B.) 5' precursor probe C.) 3' 
precursor probe.  Error bars are SEM of three determinations.     
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Analysis of the In Vivo 21S Intermediate Ribosomal Protein Composition 
 
Sequential addition of 30S ribosomal proteins in vitro revealed that a 
subset of proteins was critical to initiate folding of 16S rRNA.  The organization 
and presence of these proteins alters the conformational state of the ribosomal 
complex.  In addition, the alternate and transient conformations that are seen in 
vitro are likely to occur during assembly in vivo (Culver 2003). Characterizing the 
RNA structure and protein composition is critical for understanding the 
conformation of the p30S intermediate from drug treated cells. Two-dimensional 
gel electrophoresis was employed to identify which proteins were present in the 
p30S intermediate from drug treated cells. The p30S region was isolated from 
sucrose gradients of cells grown with 35S-methionine treated with or without 
antibiotic as described in Figure 13. Proteins from p30S, p30Sneo, and p30Sparomo 
were isolated and resolved on an 18% polyacrylamide two-dimension gel (Figure 
17).  Liquid scintillation counting of excised protein spots indicated an increase in 
radioactivity of fractions 9-16 pooled from the precursor region of sucrose 
gradients treated with antibiotic as compared to untreated samples.  In the 
absence of antibiotic, cells are naturally producing some precursor; therefore, 
proteins present in these cells served as the background.  For antibiotic treated 
cells, 35S-methionine incorporation into proteins identified in this region equal to 
or above non-drug samples were considered present.  Of the 21 30S ribosomal 
proteins, 11 were present in the precursor particle from cells treated with 
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neomycin (p30Sneo) as shown by the increase in 35S-methione incorporation 
compared to cells without antibiotic (Figure 18A). Similar results were found in 
cells treated with paromomycin where 10 proteins were present. A comparison of 
the p30Sneo and p30Sparomo protein content with the p30S intermediate (Nomura 
1973), and in vitro intermediate RI (Held 1974) is shown in Table 1.   
The protein content of the p30Sneo and p30Sparomo was similar with the 
exception of S4 which was absent in the p30Sparomo intermediate.   There was a 
greater difference between the neomycin and paromomycin intermediate 
compared to the RI particle.  These differences may reflect the use of mature 
RNA in reconstitution experiments versus precursor RNA in cells. 
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Figure 17  2D Gel Electrophoresis Pattern of 30S Ribosomal Proteins.  An 18% 
polyacrylamide gel of ribosomal proteins from the p30S intermediate. The protein 
pattern was also the same for the p30Sneo and p30Sparomo intermediates. Prior to 
protein extraction, each 35S-methionine labeled intermediate particle was mixed 
with 100 μg of non radio labeled 30S proteins for spot detection. Electrophoresis in 
the first dimension was 5 hrs at 100V and the second dimension 18hrs, followed by 
Comassie Blue staining. Each spot was excised from the gel, digested with 30% 
hydrogen peroxide and the radioactivity in the proteins were detected by liquid 
scintillation counting.    
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Figure 18  Radio labeled Ribosomal Proteins Present in the Assembly 
Intermediate from Antibiotic Treated Cells.  A.) Ribosomal proteins present in the 
precursor particle from cells treated with neomycin (10μg/ml) or B.) paromomycin 
(10μg/ml). Solid grey bars represent the threshold level of radioactivity of proteins 
isolated from the precursor from cells without antibiotic treatment (same in A and 
B). A representative threshold level for each protein is represented by the dashed 
line. However, each ribosomal protein in the p30Sneo and p30Sparomo was 
compared to the corresponding protein from the p30S region of untreated cells. 
The amount of radioactivity is represented as the percent of the total radioactivity 
in each gel and mean of three experiments. The differences in methionine 
content in the ribosomal proteins were normalized by a procedure described by 
Giri and others by dividing the radioactivity present in each protein by the number 
of methionine residues for the protein (Giri and others 1984). The proteins with 
 *           *     *      *           * * * *
*
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an asterisk were considered to be absent in the antibiotic treated intermediates.  
Error bars represent the SEM of the mean of 3 gels. 
 
Table 1  30S Ribosomal Proteins Present In The Precursor Region of Sucrose 
Gradients From Antibiotic Treated Cells. 
Proteins that were judged to be present in the isolated 30S precursor labeled 
with methionine are indicated with a (+). The third column represents ribosomal 
proteins present in the natural 21S assembly intermediate (p30S) (Nomura 1973) 
and the fourth column the in vitro 21S reconstitution intermediate (RI) (Held 
1974; Culver 2005). 
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Antibiotic Binding to the In Vivo Assembly Intermediate 
Hybridization experiments (Figure 14B-C) identified 16S rRNA in the p30S 
ribosomal intermediates in cells grown with neomycin and paromomycin.  Other 
analysis have shown that aminoglycosides can bind to 16S rRNA in the absence 
of ribosomal proteins.  It is therefore likely that the p30S intermediate particle that 
contains a partial protein content is capable of binding antibiotic as well.  In vivo 
and in vitro binding assays were conducted to determine if the precursor particle 
was capable of binding radio labeled antibiotics.  Streptomycin was added to 
enhance neomycin and paromomycin binding (Lando and others 1976) and the 
data revealed that binding of paromomycin increased by 60 % (Figure 19). Figure 
20 shows sucrose gradient profiles from cells grown with radio labeled 
antibiotics. 3H-antibiotic binding to rRNA was seen in the p30S region of the 
gradient.  As expected, the sucrose gradient profile also shows specific binding 
to the 30S subunit and this was comparable to the binding shown for neomycin to 
the 21S intermediate (Figure 20A).  Paromomycin had a less inhibitory effect on 
cell growth and decreased binding to the 21S particle is evident in Figure 20B.  
Neomycin and paromomycin binding was observed to 50S subunits as well 
(Figure 20 A-B). 
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Figure 19  Streptomycin Enhances Paromomycin Binding to the In Vivo 30S 
Assembly Intermediate. Cells were grown in the presence of 3H-paromomycin 
(4μg/ml) (●) or with streptomycin (♦) (2μg/ml) and 3H-paromomycin (4μg/ml).  
Cell lysates were separated on 5-20% R buffer sucrose gradients. Without 
streptomycin maximum binding occurred at 300 cpm (●) (fraction 13) and with 
streptomycin at 1000 cpm (♦) (fraction 13).  
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Figure 20  Aminoglycoside Binding to the In Vivo 30S Assembly Intermediate. 
Cells were grown in the presence of A.) 3H-neomycin (◊) or B.)3H-paromomycin 
(○). Non radio-labeled neomycin or paromomycin were added at 10µg/ml and 
streptomycin at 2µg/ml.  
   
Filter binding assays were performed to study neomycin and paromomycin 
binding in vitro.  Isolated p30S from pooled fractions (9-15) of sucrose gradients 
(Figure 13 A-B) were dialyzed against R buffer to remove bound antibiotic. Figure 
21 shows an increased concentration dependent binding of 3H-paromomycin to 
50S, 30S, and p30S particles.  The amount of binding correlates with the 
difference in size of each particle.    Although binding to 50S particles was not 
expected, similar results were seen with paromomycin binding to streptomycin 
sensitive ribosomes (Lando and others 1978) and with neomycin (Dahlberg 
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1978; Misumi 1980).  Particle binding did not reach saturation so an association 
constant could not be determined. Nevertheless, these results do show that the 
isolated p30S particle is capable of binding antibiotic with a similar affinity as 30S 
subunits. 
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Figure 21  In Vitro Binding Of 3H-Paromomycin to E. coli Ribosomal Subunits and 
the 21S Precursor Particle.  3H-paromomycin (Moravek Biochemicals) was used. 
5 pmoles of 30S (□) or 50S (∆) ribosomal subunits or p30S (○) precursor were 
used.  The p30S particle was isolated from cells as described in Figure 13A-B. 
Results are shown as SEM three determinations.  
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Inhibition of 30S Assembly In Vitro 
 
Ribosomal reconstitution allows an in depth analysis of the functional roles 
of individual components in both subunit assembly and ribosome function. 
Studying subunit assembly in vivo is often difficult because genetic mutations are 
frequently lethal. Reconstitution can be performed using modified or mutated 
rRNA transcripts and recombinant proteins to examine assembly in vivo (Culver 
2003). Therefore, 30S assembly inhibition by neomycin and paromomycin was 
examined using ribosomal reconstitution. Figure 22A represents the 
sedimentation profiles of 16S rRNA, 30S, and 50S subunits isolated from cells 
labeled with 3H-uridine. The 21S particle (RI) was formed by reconstitution of 16S 
rRNA and 30S ribosomal proteins at 4°C.  The fraction number corresponding to 
the peak for each particle was plotted versus its sedimentation coefficient and the 
standard in shown in Figure 22B. The sedimentation values of the intermediates 
produced in later reconstitution experiments were determined using the equation 
of the slope in Figure 22B.  
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Figure 22  Sucrose Gradient Profiles and Standard Curve for Sedimentation 
Coefficients for Ribosomal Subunits and 16S rRNA.  A.) Sucrose gradient 
profiles for 3H-uridine labeled 16S rRNA (●), the 21S reconstitution intermediate 
(RI) (▲), 30S subunit (■), 50S subunit (●). The subunits and rRNA were isolated 
from cells and centrifuged on 5-20% S buffer sucrose gradients. B.) A standard 
curve showing the linearity of the sucrose gradient and sedimentation of each 
particle. The peak fraction from the sucrose gradient in 23A is plotted on the X-
axis versus the S value of the particle (Y-axis).   
 
 16S rRNA isolated from 3H-uridine labeled cells was reconstituted with a 
four fold molar excess of 30S ribosomal proteins. The sucrose gradient profile in 
Figure 23A shows complete assembly of a 30S subunit from reconstitution 
performed at 40°C. The activity of the reconstituted subunits were not examined, 
but others have shown that reconstitution performed with the conditions 
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described in this study are capable of poly phenylalanine synthesis and 
reassociation with 50S subunits (Spedding 1990).  
 Traub and others have shown that reconstitution at 4°C produces a 
particle, RI, with a sedimentation coefficient of 21S (1971). These conditions 
were used to produce the RI particle in Figure 23A, which later was compared to 
the intermediates produced in the presence of drug. The intermediate formed at 
4°C represented the maximum amount of 21S formation under the above 
conditions.   
 Figure 23B shows reconstitution of 30S subunits at 40°C with a 10,100, 
and 1000-fold excess of neomycin or paromomycin. Increasing concentrations of 
the antibiotic inhibited the reconstitution of the RNA into a 30S subunit.  The 
intermediate produced by neomycin was RIneo with a sedimentation coefficient of 
21S. Reconstitution with 0.4μM neomycin did not produce an intermediate 
particle suggesting that the RNA and proteins were not able to assemble under 
these conditions.  In contrast, reconstitution with paromomycin at the same 
concentration resulted in a 21S particle (RIparomo).  This result also occurred with 
0.2 and 0.04μM of paromomycin. 
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Figure 23  Inhibition of 30S Assembly In Vitro by Aminoglycosides. A.) 30S 
reconstitution in the absence of antibiotic at 40°C (□).  0.5 A260 units of 3H-16S 
rRNA and 2.0 A260 of total 30S ribosomal proteins were used. Reconstitution 
performed under the same conditions except at 4°C produced a 21S particle (RI) 
(○). The reconstituted particles were layered on 5-20% sucrose gradients in buffer 
# 7 and the profiles were determined by liquid scintillation counting following 
centrifugation. B.) 30S reconstitution at 40°C was performed as described in A. 
but in the presence of neomycin, 0.04μM (∆), 0.2 μM (▲), and 0.4 μM (□) C.) 30S 
reconstitution at 40°C with 0.04μM (○), 0.2 μM (●), and 0.4 μM (□) of 
paromomycin.  
           
 Increasing concentration of neomycin and paromomycin resulted in a 
decrease in 30S subunit formation (Figure 24), suggesting that smaller amounts 
of RNA were able to associate into a complete particle.  On the other hand, the 
increased amount of RIneo or RIparomo at the lower concentration of drug shows 
that a greater amount of RNA was capable of reconstituting and possibly 
proceeding to 30S assembly.   While more precursor accumulation is seen in 
vivo, reconstitution examines RNA folding and protein association, and the 
factors that would limit the formation of 30S assembly. 
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Figure 24  The Percent of 30S Formation with Increasing Concentration of 
Neomycin or Paromomycin.  The amount of 30S formation is represented as a 
percent of the sum of radioactivity in the RIneo and RIparomo particles (fractions 9-
16) and the total amount of RNA from each sucrose gradient in Figure 24. The 
maximum amount of precursor formed without drug is RI as shown in Figure 24A, 
neomycin (∆), and paromomycin (○).  Data are shown as the SEM and the mean 
of three experiments. 
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CHAPTER 4 
 
DISCUSSION 
 
 
 This work supports earlier findings that showed a number of antibiotics that 
inhibit translation in cells also prevent ribosomal subunit assembly.  Previously, 
erythromycin was found to inhibit ribosome assembly in E.coli in a fashion similar 
to the present studies using neomycin and paromomycin.  A 50S precursor 
particle sedimenting in the 30S region of sucrose gradients from erythromycin 
treated cells contained 23S rRNA and bound antibiotic both in vivo and in vitro on 
the 50S subunit.  In addition, the 50S precursor contained 18 of the 34 ribosomal 
proteins (Usary and Champney 2001).  The translational inhibitors neomycin and 
paromomycin prevent 30S subunit assembly in a similar manner to what was 
observed for 50S assembly.   
The intent of this work was to explore the features 30S assembly inhibition 
by these antibiotics.  The in vivo precursor particle that accumulated in the 
presence of neomycin and paromomycin was characterized by identifying the 
protein composition, rRNA content, and antibiotic binding.  Both antibiotics were 
capable of binding to the p30S assembly intermediate with neomycin having a 
greater affinity. Hybridization analysis confirmed that the 21S particle that bound 
both antibiotics was composed of both 16S and precursor 17S rRNA, showing 
that it was truly a stalled intermediate of the 30S subunit.  Furthermore, the 
ribosomal protein composition of this intermediate was identified.   
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Neomycin and Paromomycin Binding to the 30S Assembly Intermediate 
  Binding assays revealed that the p30S intermediate and mature 30S 
subunits bound neomycin and paromomycin (Figures 19-21). This result was 
expected because that paromomycin binds to specific nucleotides of 16S rRNA 
in vitro, and that this interaction is important for antibiotic activity (Fourmy and 
others 1996,1998; Recht and others 1999). Furthermore, paromomycin binding 
induced a conformational change in the A site stabilizing RNA-RNA interactions 
(Fourmy 1999, Barbieri 2007).  Footprinting analysis also revealed considerable 
protection of nucleotides in the A site when neomycin and paromomycin were 
bound to protein-free 16S rRNA (Purhoit and Stern 1994).  These observations 
suggest possible interactions of the antibiotics with RNA before the native 30S 
conformation is stabilized (Fourmy and others 1996, 1998).  Such findings 
support the hypothesis that the antibiotics inhibit assembly by interacting with 
16S RNA as the subunit forms.  
In the binding studies using radio labeled antibiotics, neomycin bound to 
particles with a greater affinity.  The total amount of radioactivity in the p30S 
region of the gradient increased by 25% for cells treated with 3H-neomycin 
(Figure 20) compared to 3H-paromomycin.   Initial studies on assembly inhibition 
had shown that in both S.aureus and E.coli, there was a similar reduction in 
growth rate and 30S formation with neomycin than with paromomycin (Mehta and 
Champney 2002, 2003). The two antibiotics are similar in structure, but the 
difference in one functional group can affect binding to RNA.  Specificity of 
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aminoglycosides for the A site is a result of eight direct contacts between the 
conserved neamine core, but each antibiotic can make additional contacts within 
the A site, increasing specificity.  Crystal structures of aminoglycosides 
complexed with A site RNA revealed that the number of antibiotic molecules 
occupying the A site were dependent on the number of rings and positive 
charges (Francois and others 2005).  Kinetic analysis from several other groups 
also revealed that neomycin binds with a greater affinity to the A site than does 
paromomycin and other aminoglycosides (Benveniste and Davies 1973; Francois 
and others 2005). 
One possible explanation for the increased binding of neomycin over 
paromomycin may be due to the amino group in neomycin, which increases the 
net charge to +6.  This may facilitate an additional contact with the negatively 
charged RNA, relative to a hydroxyl group at C'6 of ring I in paromomycin.  While 
this may contribute to antibiotic binding, a more plausible explanation could 
involve the position of the additional positive charge.  Ring I establishes initial 
antibiotic and RNA contacts by forming a pseudo base pair with A1408.  This 
allows the neamine core to stack above base pairs A1409:U1491 and 
A1406:U1495.  These specific contacts mediate the “flipping out” of adenines 
1492 and 1493, the structural rearrangement that induces misreading (Ogle and 
others 2002, 2003; Westhof and Vicens 2003).   
Studies have shown that mutations in nucleotides of the A site that bind 
aminoglycosides distinctly affect those with an OH group versus NH3 (Pfister and 
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others 2005).  Mutations of A1409 and A1491 in 16S RNA revealed that 
aminoglycosides with an OH at position C'6 developed increased resistance and 
interrupted stacking with A1409:A1491. Although neomycin and paromomycin 
were able to base pair with A1408, the NH3+ group was able to compensate for 
the stacking disruption.  Moreover, of the aminoglycosides examined, neomycin 
exhibited the greatest affinity for the mutant ribosomes.  Others have suggested 
that the three additional hydrogen bonds formed with neomycin, as well as the 
energy difference resulting from the charged NH3+ hydrogen bond, contribute to 
this association (Pilch and others 2003).   
Binding to the 50S Subunit 
Many of these features might explain neomycin and paromomycin binding 
to the 50S subunit (Figure 20-21).  Although the literature supports that neomycin 
and paromomycin are specific for the 30S subunit, binding was observed to the 
large subunit both in vivo and in vitro.  Studies by Lando and others described 
similar binding of paromomycin to 50S subunits in vitro (1978).  Also antibiotic 
competition assays between kanamycin and neomycin resulted in reduced 
kanamycin binding to 50S and 30S subunits by 90%.  This was not observed with 
streptomycin, which is not specific for the ribosomal A site (Misumi and others 
1978).  Electrophoretic mobility shift assays of ribosome cell lysates treated with 
neomycin showed an increased mobility of both 30S and 50S particles, 
suggesting the drug was capable of binding to and causing structural 
arrangements of both particles (Dahlberg and others 1977).   
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These 50S interactions are not surprising considering the promiscuous 
nature of these antibiotics. Aminoglycosides are capable of binding to several 
RNA motifs such as RNA aptamers, the HIV Rev Response element, and group I 
introns (Ashen and others 1991, Zapp and others 1993). Their flexibility around 
the glycosidic bonds and positive charge makes them suitable candidates for 
interaction with a myriad of RNA molecules (Tor 2006).  Thus, these 
investigations highlight a new exploratory feature for these drugs.  However, 
these data are not sufficient to allow any specific conclusions, but it must be 
noted that they have no specific effect on 50S assembly and do not stimulate 
turnover of 23S RNA (Figure 15) (Mehta and Champney 2002, 2003).  
Ribosomal RNA Analysis 
Analysis of rRNA from the stalled intermediates in cells treated with 
neomycin and paromomycin revealed an accumulation of 16S rRNA in the 21S 
precursor region of the gradient (Figure 14B-C).  This further substantiates 
findings that the antibiotic binds specifically to the 16S rRNA of the assembly 
intermediate.   The presence of precursor RNA in this particle indicates that 
neomycin and paromomycin are indeed inhibiting the maturation of 30S subunits.  
Similar results have been seen in cells defective in a number of ribosomal 
assembly factors such as chaperones and GTPases (Charollias 2003). A 
temperature sensitive mutation of the heat shock protein DnaK in E.coli caused 
defects in the later stages of ribosome biogenesis.  This was evident by an 
accumulation of unprocessed forms of 16S and 23S rRNA from 21S, 32S, and 
76 
 
45S ribosomal intermediates.  Era, a GTPase binding protein essential for cell 
growth in E.coli,  binds to 30S subunits as well as 16S rRNA in vitro.  Depletion 
of the protein resulted in an accumulation of precursor 16S rRNA and a decrease 
in 70S ribosome formation (Sayed and others 1999).  Cells containing mutations 
in several other GTPases, such as RsgA and YrdC, also resulted in an 
accumulation of immature 16S rRNA (Himeno and others 2004; Kaczanowska 
and Aulin 2005).  Altogether, these ribosomal factors assist in the RNA 
conformational rearrangements necessary for subunit formation.  In the absence 
of these factors, assembly is incomplete as is evident by 21S precursor and 
immature rRNA accumulation.  Interestingly these results show that 
aminoglycosides produce similar assembly defects. 
Northern hybridization analysis revealed differences in RNA processing 
in the presence of both antibiotics.   Antibiotic treatment had a greater effect on 
maturation of the 5' end (Figure 15-16). This was surprising considering the 
polarity of transcription. The differences in 5' and 3' precursor observed in these 
studies may reflect the importance of the 5' precursor during assembly.  Beascon 
and Wagner revealed that 5' leader sequences are critical during the early stages 
of assembly.  Their kinetic analysis showed that the leader sequences formed 
transient interactions with the 5' domain of 16S RNA, and deletions in this region 
resulted in major assembly defects. They concluded that the 5' leader was 
needed to prevent premature folding of 16S RNA during assembly (1999).   
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Ribonuclease III was shown to cleave RNA sequences at the 5' end of 
17S rRNA but only after the addition of ribosomal proteins, suggesting that the 
final maturation of 16S rRNA depends on the formation of the ribonulceoprotein 
complex (Srivastava 1990). In addition, formation of the RI intermediate largely 
consists of arrangements in the 5' and central domains therefore these regions 
are probably protected by RNA-RNA or protein interactions.  On the other hand, 
the 3' domain consisting of minor RNA conformations is readily accessible and is 
sufficient for RNase cleavage.  
 This, however, does not sufficiently explain RNA degradation observed 
in the presence of both antibiotics.  While the 3' end is more accessible as 
assembly proceeds, degradation of the 3' end is probable in abnormal cells given 
that exonuclease activity begins at the 3' end. Thus, greater amounts of 5' 
precursor would be present compared to 3' precursor RNA.  
The difference in amounts of 5' or 3' precursor may also reflect the affinity 
or neomycin and paromomycin for the p30S intermediate. Treatment with 
paromomycin resulted in larger amounts of 3' precursor (Figure 16).  The 
decreased affinity of paromomycin for the p30S intermediate would result in 
faster dissociation from the particle making it less susceptible to RNA 
degradation.  Exploration of this claim requires further examination of RNA 
processing.  Nevertheless, these results support the idea that aminoglycosides 
perturb assembly by affecting RNA conformational changes needed to form 
mature functional 30S subunits. 
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Ribosomal Protein Analysis 
The precursor particle from antibiotic treated cells contained a different 
protein composition compared with the natural 21S (p30S) particle (Nomura 
1973).  The dissimilarity could indicate how these antibiotics affect protein-RNA 
conformations during assembly.  In the p30S particle tertiary proteins S2, S3, 
S10, S14, and S21 are missing in addition to three secondary proteins.   In 
contrast, the paromomycin stalled intermediate included S3, S10, and S14, and 
neomycin produced an intermediate with tertiary proteins S10 and S14 (Figure 
25).  In vitro association of these proteins can only occur following an energy 
dependent rearrangement of the RNA in the precursor from 21S to 26S. This 
transition creates functional binding sites for the tertiary proteins as well as the 
30S subunit.  The presence of S3, S10, and S14 in the antibiotic intermediate 
could suggest that some structural features akin to the 30S may be present in the 
21S particle.  In addition, protein binding of S3, S10, and S14 is interdependent 
and forms a hydrophobic core within the RNA, a feature that could stabilize 
antibiotic interactions.   
Analysis of 21S intermediates from chaperone deficient cells also revealed 
differences in protein composition.  Ribosomal proteins S1, S14, and S21 were 
absent in 21S particles isolated from cells missing ObgE (Sato and others 2005).   
In the absence of chaperone DnaK, 21S intermediates did not contain S3, S10, 
S14, S21, S2, and S5 (El Hage and Alix 2004).  These variations indicate that not 
all p30S precursors are identical in spite of having the same S value, and that 
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they differ in protein content, indicating flexibility in the formation of 21S 
intermediates.  In addition, multiple pathways may exist to form a functional 30S 
subunit and initial stages may allow flexibility in the order of protein folding or 
association. However, the 21S and 26S particles have been identified to be the 
most critical particles (reviewed in Culver 2003).   
The absence of S8 in the precursors resulting from antibiotic treatment 
further supports the hypothesis that different structural arrangements occur 
during assembly.  A primary binding protein, S8 stabilizes the central domain and 
provides binding sites for S6 and S18.  Ribosomal protein S8 is also required for 
subsequent binding of S5 and S12, which are absent in the p30Sneo and 
p30Sparomo intermediates (Figure 25).  The absence of this protein suggests that 
neomycin and paromomycin may indirectly affect formation of the central domain 
or that an alternate mode for its formation exists.  In the absence of primary 
protein S15, 30S subunits were able to assemble in vivo.  However, under 
suboptimal conditions or in vitro, subunits failed to assemble.  Chemical probing 
and primer extension of mutant subunits revealed a similar protection pattern 
with wild type cells suggesting that the structure was the same.  S15 forms 
binding sites for secondary proteins, but Orr and others showed that Mg2+ can 
cause similar changes in RNA structure to facilitate S15 binding (1998).  
Aminoglycoside binding rearranges the massive 30S structure, moving its head 
(5' domain) towards its body (3' domain), so it is not likely that compensatory 
rearrangements can occur during assembly. This may actually allow the drug to 
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be more accessible to the RNA during assembly, potentially locking the RNA in a 
conformation that precludes the addition of other proteins.   
 
 
Figure 25  Ribosomal Proteins Missing in the p30S Particles from Antibiotic 
Treated Cells.  Proteins circled in black were absent in the p30neo and 
p30Sparomo assembly intermediates.  The absence of proteins circled in yellow 
was dependent on the antibiotic used (Table 1).   
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Structural Comparison of Assembly Intermediates 
 
The results of this work have provided insight on the features of 30S 
ribosomal subunit assembly inhibition by neomycin and paromomycin in 
identifying the ribosomal RNA and protein content of the precursor particle.    The 
data show that neomycin and paromomycin can impair this process producing a 
21S intermediate (Figure 9). However, the extent of assembly inhibition is equal 
to the extent of protein synthesis inhibition (Champney 2003), implying a 
heterogeneous population may exist.   
Structural data show that in normal cells that RNA undergoes successive 
changes in structure at each intermediate step.  More than 50% of the changes 
observed during the 16S to 21S transition occur in the 5' and central domains.  
While assembly proceeds with transcriptional polarity, minor changes in the 3' 
domain take place in this early stage.  A continuation of protection in certain 
domains or an incremental change in reactivity of 11 nucleotides during all three 
stages represents the dynamics of this concerted process (Holmes and Culver 
2005). 
The data presented here show that these assembly pathways are not 
congruent and that other features may exist for antibiotic binding to the stalled 
intermediate.  In normal assembly, the decoding center forms subsequent to the 
21S to 26S transition.  Included in this stage is rearrangement of the 530-stem 
loop that forms the central psuedoknot connecting the head, body, and platform.  
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The addition of tertiary proteins in the last assembly step (26S to 30S) results in 
accommodation of sites formed in the previous step and formation of the 
decoding pocket.  In addition, protections of nucleotides C1399-G1504, which 
are adjacent to the decoding region, occur during this stage (Holmes and Culver 
2004).  We have identified an intermediate particle which includes three of the 
tertiary proteins responsible for these late assembly transitions but sediments at 
21S.  These differences may enhance drug binding during assembly and indicate 
important features of a novel target for aminoglycosides in cells.  
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